Trial of Iressa in Prostate Cancer Patients

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: Gefitinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00265070

1839IL/0093

Details and patient eligibility

About

This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.

Enrollment: 80 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Removal of prostate for prostate cancer
• Raised level of prostate specific antigen (PSA) post-surgery
• Can have received some radiation therapy

Exclusion criteria

• Any after surgery male hormone blocking therapy.
• Low white blood cell count
• Abnormal liver function test

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)